Léonard Jean-Francois, Courcol Martine, Gautier Jean-Charles
Disposition, Safety and Animal Research, sanofi-aventis R&D, Vitry-sur-Seine, France.
Methods Mol Biol. 2011;691:351-68. doi: 10.1007/978-1-60761-849-2_22.
The surface-enhanced laser desorption ionization (SELDI) technology is a promising approach not only for the research of biomarkers in the blood of patients in clinical applications but also in preclinical studies to assess the drug-induced toxicities. The optimization of the SELDI platform is a crucial step before running plasma samples from preclinical toxicity studies. First, mass spectrometer parameters such as the laser energy and ion focus mass values should be assessed in order to obtain the highest quality of spectra. Second, the coefficient of variation of the intensity, resolution, and signal-to-noise ratio of the peaks detected in reference samples should be evaluated and used as quality control criteria. Last, a systematic evaluation of technical bias such as the spot and chip position and the bioprocessor sequence number may be achieved using the appropriate multivariate statistical analyses.
表面增强激光解吸电离（SELDI）技术不仅是临床应用中研究患者血液生物标志物的一种有前景的方法，也是临床前研究中评估药物诱导毒性的一种有前景的方法。在运行临床前毒性研究的血浆样本之前，优化SELDI平台是关键步骤。首先，应评估质谱仪参数，如激光能量和离子聚焦质量值，以获得最高质量的光谱。其次，应评估参考样本中检测到的峰的强度、分辨率和信噪比的变异系数，并将其用作质量控制标准。最后，使用适当的多变量统计分析可以对技术偏差进行系统评估，如斑点和芯片位置以及生物处理器序列号。
